Short Interest in GeoVax Labs, Inc. (NASDAQ:GOVX) Decreases By 79.2%

GeoVax Labs, Inc. (NASDAQ:GOVX) saw a large decline in short interest in July. As of July 15th, there was short interest totalling 261,500 shares, a decline of 79.2% from the June 30th total of 1,260,000 shares. Based on an average trading volume of 2,970,000 shares, the days-to-cover ratio is currently 0.1 days. Currently, 5.3% of the company’s stock are short sold.

GeoVax Labs Trading Up 1.6 %

Shares of NASDAQ GOVX traded up $0.04 during trading hours on Friday, hitting $2.62. The stock had a trading volume of 264,185 shares, compared to its average volume of 1,373,865. The firm’s 50-day moving average price is $2.25 and its two-hundred day moving average price is $2.43. GeoVax Labs has a 52 week low of $1.09 and a 52 week high of $9.75.

GeoVax Labs (NASDAQ:GOVX) last posted its earnings results on Tuesday, May 14th. The company reported ($2.47) earnings per share for the quarter. On average, research analysts predict that GeoVax Labs will post -7.41 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in GeoVax Labs stock. Armistice Capital LLC bought a new stake in GeoVax Labs, Inc. (NASDAQ:GOVX) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,626,516 shares of the company’s stock, valued at approximately $587,000. Armistice Capital LLC owned approximately 91.38% of GeoVax Labs at the end of the most recent quarter. 6.09% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Roth Capital raised GeoVax Labs to a “strong-buy” rating in a research note on Tuesday, July 16th. EF Hutton Acquisition Co. I raised GeoVax Labs to a “strong-buy” rating in a research note on Tuesday. Roth Mkm started coverage on GeoVax Labs in a research note on Tuesday, July 16th. They issued a “buy” rating and a $20.00 price target for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $8.00 price target on shares of GeoVax Labs in a research note on Tuesday, July 2nd.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.